VIENNA, Austria, September 3 /PRNewswire/ --

- Report of Positive Results with Innovative Pro-Healing Stent is 
Featured at ESC Congress 2007

OrbusNeich today announced that post-marketing data from patient subsets
of a global registry support the use of the company's Genous(TM)
Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European
Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from
OrbusNeich's e-HEALING registry show:

-- For 296 diabetic patients at six months, the target lesion
       revascularization (TLR) rate was 2%, which is much lower than was
       anticipated

    -- A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]
       six months

    -- For 923 patients with statin use, the major adverse cardiac events
       (MACE) rate at six months was 5.7%, while 116 patients without statin
       use experienced a MACE rate of 6.9% over the same period



"This real-world data strengthen our belief that Genous is a very
promising alternative to drug-eluting stents," said de Winter, a co-principal
investigator of the study and director of the catheterization laboratory at
the Academic Medical Center in Amsterdam. "Genous appears to have the same
efficacy as drug-eluting stents but a better safety profile with only minimal
dual-antiplatelet therapy requirements. This is an important finding in that
physicians are becoming reluctant to burden their patients with the cost and
compliance issues associated with drug-eluting stents and their extensive
dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United
States) prospective registry of patients treated with the Genous
Bio-engineered R stent in accordance with the instructions for use. The
protocol recommends that patients receive two weeks of statin treatment prior
to the procedure and one month of clopidogrel treatment after the procedure.
Clinical follow-up takes place at 30 days, six months and 12 months. The
primary outcome of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody,
captures a patient's endothelial progenitor cells (EPCs) to accelerate the
natural healing process. EPCs circulate in the bloodstream and are involved
in the repair of blood vessels. When attracted to the surface of Genous, EPCs
rapidly form an endothelial layer over the stent that provides protection
against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical
devices for the treatment of vascular diseases. The company's product
portfolio includes the Genous(TM) Bio-engineered R stent(TM), an
antibody-coated device that is the first-ever stent to capture a patient's
endothelial progenitor cells (EPCs) to accelerate the natural healing process
following placement. Other products are stents, balloons and guiding
catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM),
Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has
operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and
Shenzhen, China. OrbusNeich, which has provided cardiology devices to
physicians through its predecessor companies since 1979, today supplies
products in more than 60 countries. For more information, visit
www.OrbusNeich.com.

Web site: http://www.OrbusNeich.com